Research Article

Quality Appraisal of the Pharmacoeconomic Research Literature about Antivirals: A Comparison between Chinese Medicine and Non-Chinese Medicine

Junliang Zhang, Qian Bai, and Ying Bian

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, China

Correspondence should be addressed to Ying Bian; bianying@um.edu.mo

Received 15 January 2021; Accepted 8 July 2021; Published 22 July 2021

Academic Editor: Fadia S. Youssef

Copyright © 2021 Junliang Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Antiviral activity is a main function of many types of traditional Chinese medicine (TCM), and they may contribute more in the process of certain viral epidemics. Therefore, based on the effectiveness and economy of TCM, we aimed to determine the situation of health economic studies about antivirals, especially the difference between TCM and non-TCM. Methods. A literature search of three databases was conducted with a time range of January 2000–December 2020, and terms related to health economics and TCM were used as key terms. QHES and CHEERS were used as quality assessment tools. Results. 203 papers were included in our research. After evaluation using QHES and CHEERS, antiviral TCM obtained an overall score of 41.37 ± 4.46/99 in QHES, compared with 48.89 ± 7.25/99 (18.18% higher than TCM) of antiviral non-TCM. Conclusion. With a statistically significant difference, the overall quality of pharmacoeconomic research about antiviral non-Chinese medicine is better than that about antiviral Chinese medicine, which may have resulted from researchers’ capacities or the absence of a more suitable standard for pharmacoeconomic research. It tells that the quality of pharmacoeconomic studies about TCM still warrants improvement.

1. Introduction

Viral infection has become one of the main causes of infectious diseases in humans. Reportedly, >10% of the world’s population are infected with viruses like HIV and hepatitis C and B, all of which can cause severe diseases and even death during their progression [1]. In the course of fighting viruses, humanity has discovered thousands of natural products and invented medicines based on them. These medicines have saved many people’s lives, resulting in a decrease of the mortality rate caused by virus infection [2, 3]. Meanwhile, the recent COVID-19 pandemic, which has posed tremendous threats to the global public health system, has made pharmacotherapy for COVID-19 a concern for many researchers and medical practitioners all over the world. Even though no specific medicine is recommended to prevent or treat COVID-19, it is still significant for us to know more about antiviral drugs, since drug therapy is the most efficient way to cure viral infection. According to some experts’ estimations, the novel coronavirus (SARS-CoV-2) will coexist with human beings for a long time, seriously threatening our public health [4]. Therefore, as one of the most important weapons in the fight against pathogenic viruses, antiviral drugs, including traditional medicine, should receive attention and be valued, especially their safety, efficacy, and economic value.

Among all traditional medicines around the world, traditional Chinese medicine (TCM) has gained extensive attention because of its potential effectiveness and economic value since the COVID-19 outbreak in Wuhan, China. During the COVID-19 epidemic in China, several Chinese medicine prescriptions were promoted as routine prescriptions for the prevention and treatment of COVID-19 such as qingfei paidu decoction, gancaoganjiang decoction, and sheganmahuang decoction [5]. This marks that practitioners’ recognition of TCM has risen to the level of clinical
policy. Besides, as a main function of TCM, the antiviral effect in TCM has been researched in recent decades. In the process of discovering ways of treating COVID-19, researchers found a potential correlation between injections of Chinese medicine and some key targets through research methods like network pharmacology [6]. As for the activity of treating COVID-19, some classic proprietary Chinese medicines such as lianhuaqingwen capsules have been demonstrated to show antiviral and anti-inflammatory activity against novel coronavirus [7]. Cui et al. reviewed TCM for COVID-19 treatment and they summed up the clinical outcome, pathogenesis, and present application of TCM used to treat COVID-19 [8]. These could demonstrate the effectiveness of TCM in treating COVID-19 to some extent.

Considering that TCM could also function when used to treat viral infection, its safety, efficacy, and economy should be evaluated in clinical practice. However, studies evaluating the economics of TCM were unsatisfactory. Dujun reviewed the research development of pharmacoeconomic evaluation on TCM as of 2009 [9]. They found the literature on the economic evaluation of traditional Chinese medicine insufficient. Moreover, some problems existed in TCM pharmacoeconomic studies, including limited evaluation methods and less rigorous study design; therefore, the premarketing pharmacoeconomic evaluation on TCM remains a great necessity. These facts reveal the unsatisfactory quality of TCM’s pharmacoeconomic evaluation.

Compared with other fields of disease, there are few kinds of antiviral drugs in the fight against viruses [10]. Both TCM and non-TCM antiviral medicine have taken obvious effect in tackling viral infections. However, there is no agreement as to whether TCM antiviral medicine is superior to non-TCM antiviral medicine from the perspectives of safety, efficacy, and economic value. The comparison between TCM and non-TCM antiviral medicine, especially from an economic perspective, might contribute to priority selection toward various treatment measurements for policymakers [11]. Together with problems in related pharmacoeconomic studies, it is important to conduct a rigorous quality appraisal in this field. Therefore, we aimed to evaluate the quality of current pharmacoeconomic analysis on antiviral drugs while also comparing the quality between TCM and non-TCM antiviral medicines using main health economic evaluation tools.

2. Methods

2.1. Data Source. The literature to be appraised consisted of the Web of Science, PubMed, and China National Knowledge Infrastructure (CNKI). The former two databases encompass the bulk of studies in biomedicine and natural and social science in different countries. CNKI is China’s largest knowledge resource sharing grid platform, covering a large number of studies in every field. Therefore, pharmacoeconomic studies concerning antivirals were retrieved from the abovementioned databases.

2.2. Search Strategy. Based on the classification of health economic analysis and the research topic of antiviral drugs, we determined final research strategy as “cost-effectiveness” OR “cost-minimization” OR “budget impact analysis” OR “cost-benefit” OR “cost-utility” OR “pharmacoeconomic” OR “health economic” AND “(traditional) Chinese medicine” OR “antiviral/anti-virus.” In the same way, we search these terms in Chinese in CNKI to find the relevant literature written in Chinese. Publishing date of literature was confined from January 2000 to December 2020.

2.3. Inclusion and Exclusion Criteria. Literature with the following characteristics is included: (1) introducing original pharmacoeconomic research about antiviral chemicals or Chinese medicine with antiviral effect; (2) original health economic research on strategies that only use antiviral drugs to treat or prevent disease instead of vaccines, medical instruments, public policies, etc.; (3) papers that meet the above criteria with accessibility to the full text.

The literature with the following features would be excluded: (1) theses or dissertations that combine pharmacoeconomic studies with other content; (2) studies about pharmacoeconomic evaluation of combinations containing both Chinese and Western medicine, or both antiviral drugs and non-antiviral drugs; (3) duplicate versions that were repeatedly published or published in another language; (4) literature of news, meetings, letters, and reviews, especially those papers as an introduction to some completed pharmacoeconomic studies or methodology that were not empirical studies.

2.4. Quality Assessment. Quality of Health Economic Studies (QHES) is a validated instrument for the critical appraisal in health economic evaluation. QHES provides a checklist with 16 items, each of which is connected to specific points that also represent their weights in the whole quality assessment. By using this checklist to quantitatively evaluate the literature, each included item will get a total score that could be used in an intuitive comparison of literature quality.

In addition, Consolidated Health Economic Evaluation Reporting Standards (CHEERS) is designed to standardize and improve the reporting quality of health economic evaluations. With 24 items to be measured, CHEERS can efficiently avoid the influence of subjectivity to a certain extent, by defining the evaluation degree of the items. At the same time, CHEERS gives us a grading standard, making it complementary to QHES in actual practice. To calculate the score of each paper, we assigned a weight of “1” to papers marked “fully reported,” “0.5” to those marked “partially reported,” and “0” to those marked “unreported (if applicable).” We used QHES and CHEERS as our evaluation tools for the included literature.

In terms of the differences between the two tools above, it should be noted that the items in both checklists overlap in part. Table 1 shows the content of the items in the checklists for both tools in detail. Besides, since the weights of each level in CHEERS assessment were not designed when CHEERS was invented, unlike QHES, the scores based on the CHEERS checklist are solely for reference and the scoring results between QHES and CHEERS are not comparable [12, 13].
2.5. Statistics. SPSS Statistics 21 was used to calculate the weighted mean differences (MD), the value of OR, and the 95% confidence interval in data analysis. The Chi-square test for discrete data and t-test for continuous data were applied in our study and \( P < 0.05 \) was regarded as being statistically significant, which was marked in Table 1.

3. Results

Overall, 1,291 studies in the literature were extracted from the three databases, leaving 1,257 studies after removing duplicates. After title and full-text screening, 203 studies remained. Figure 1 is a flow diagram of the detailed search process.

Basically, Table 2 shows the situation of the included literature, which contains the classification based on several items within it. From the perspective of written language, 75.86% of all included papers were in English, while the other 24.14% were in Chinese. Generally, the pharmacoeconomic papers about antivirals written in Chinese were still fewer than those in English. Regarding the published year, there was a growing trend of antiviral publications every five years. It seems that more practitioners paid more attention to the field of pharmacoeconomic evaluation. In terms of the type of drugs, nucleoside analogs including entecavir, lamivudine, and adefovir seized the largest proportion of all literature. This was consistent with the actual use of drugs in clinical practice [14]. Hereafter, the model analysis was not widely used because 94.58% of all papers did not describe their model analysis. As for the analysis method, cost-effectiveness analysis (CEA) was undoubtedly the most common method, while budget impact analysis (BIA) was second, accounting for 8.37%; few papers chose CBA or CUA as their analysis method. Sixty-five point zero two percent of all included literature were retrospective while 34.98% were prospective. Seventy-eight point eight two percent of investigated papers were not funded, and SPSS was the most popular analysis software among the literature at 46.80%. Stata, SAS, and Microsoft Excel were also mentioned as having been used.

Table 3 illustrates the scoring result using the QHES checklist. The average scores and standard deviations of 15 items were calculated. In general, Items 12–14 and 16 showed an extremely low result score. Considering the reference range, Item 13, which represented the statement situation of the economic model, assumption, and limitation, showed the worst performance among all items in the QHES checklist. Item 4 (reference range: 0–1) refers to subgroup analysis and relevant prespecification, while none of the included literature covered subgroup analysis, and so Table 3 does not display Item 4.

The results shown in Table 4 were in accordance with the grading system of the CHEERS checklist. Twenty-three items were taken into consideration, and Items 1 (98.52% fully reported), 3 (97.04% fully reported), 5 (99.51% fully reported), and 10 (96.06% fully reported) showed excellent reporting results. Some items, like Item 9 that was 94.09% unreported, did not show an ideal result of reporting. Item 12 (measurement and valuation of preference-based outcomes) was not presented because none of the included studies were related to preference-based outcomes.

Since the evaluation result of QHES is quantitative, a comparison between Chinese medicine and non-Chinese medicine could be shown in an intuitive way as given in Table 5.

From all the data above, we could know the differences between antiviral TCM and non-TCM in a statistical manner. The scores for Items 7, 12, and 13 of non-TCM antiviral studies were significantly higher than those of the TCM antiviral studies with \( P \)-values <0.05. The scores of TCM antiviral studies were only higher than those of non-TCM studies for Items 1 and 9. Higher scores occurred in non-TCM antiviral literature for the remaining items.

4. Discussion

With the application of QHES and CHEERS, this study evaluated the reporting quality of pharmacoeconomic studies concerning antiviral medicine and the differences between TCM and non-TCM antiviral medicine. Findings identified that there was a gap in the actual situation of included pharmacoeconomic studies and the ideal quality level. Besides, the score of TCM antiviral medicine evaluations turned out to be slightly lower than those of non-TCM evaluations in most QHES items.

Obviously, the quality of literature about antiviral Chinese medicine was not high. It is believed that the pharmacoeconomic studies about TCM were generally of a low level. In 2008, Li et al. reported that they had analyzed the pertinent literature from several aspects such as author affiliation, research method, research perspective, research object, and research duration and found that many problems still remained in Chinese pharmacoeconomic evaluation studies [14]. Considering the abovementioned circumstance,
Wang et al. established guidelines for the pharmacoeco-
nomical evaluation of proprietary Chinese medicine to make
the evaluation process and results both scientific and fair
[15]. It was convincing that subsequent pharmacoeconomic
researchers could access this guideline and follow it con-
sciously [16, 17].

According to the results, the P-values of Items 7, 12, and 13
and the total score in Table 5 were <0.05, which meant the
scores of literature quality were significantly different in these
aspects. Fourteen of the 16 items showed that the scores of
antiviral non-TCM were higher than those of TCM. Item 7
refers to whether the data abstraction methodology was stated,
Item 12 refers to the clarity and transparency with which the
economic model, study methods, etc. were displayed, while Item
13 is about the statement of the choice of economic model, main
assumption, and limitation. These imply that there is still a way
to go for health economic researchers focusing on TCM, es-
pecially in the rigor of matters about the economic models and
the awareness of clarifying the methodology in their empirical
research.

Meanwhile, there were several potential reasons that
resulted in such a situation of literature quality. Most
pharmacoeconomic studies were conducted by medical
workers in hospitals, especially pharmacists [18]. It was
mentioned that the pharmacist conducting the pharma-
ecoconomic evaluation is most likely to obtain effective and
useful results by following the described analysis steps [19].
However, the need remains to improve the quality of studies
conducted by pharmacists. For medical workers in China,
their pharmacoeconomic evaluations probably arose from
their hopes of title promotion. Since practitioners in medical
institutions can be accessible to many patients who need to
take drugs periodically, it is easier for them to conduct health
economic evaluations, like comparisons of the cost-effec-
tiveness ratio of two commonly used drugs in clinics [20, 21].
Therefore, most of their original motivation was not the
economy of health insurance funding or affordability for
patients, but their personal benefit. This is an influential
factor in the literature quality.

These evaluations are of great significance because they
could provide evidence for doctors and patients when choosing
which drugs to use. It could also save funds for medical insur-
ance and the government could redistribute the money saved
to healthcare workers, thus increasing their incomes. Farid et al.
reported that, in developing countries such as Egypt, the
growing population was a threat to the allocation of the do-
mestic health system. Medical resource scarcity exists in almost
all countries and regions and if the quality of health economic
evaluations could be improved, officials in national medical
departments can make better decisions [22]. Besides, Acharya
introduced the urgent need of pharmacoeconomic studies in
Nepal [23]. For nations with little funding to develop their
medical industry, it is hard to start from zero, not to mention
improving studies’ quality. Therefore, it is also high time for

| Table 2: Description of the included literature’s information. |
|--------------------------------------------------------------|
| **Item** | **Number (%)** |
| Language | English 154 (75.86) Chinese 49 (24.14) |
| Publication year | 2000–2004 10 (4.92) 2005–2009 32 (15.76) 2010–2014 74 (36.45) 2015–2020 87 (42.87) |
| Type of drug | Nucleoside analog 90 (44.33) Chinese medicine 53 (26.11) Interferon 38 (18.72) Others 22 (10.84) |
| Model analysis | Described 11 (5.42) Not described 192 (94.58) |
| Analyzing method | CEA 148 (72.91) CBA 6 (2.96) CUA 2 (0.99) BIA 17 (8.37) Others 30 (14.77) |
| Design method | Retrospective study 132 (65.02) Prospective study 71 (34.98) |
| Fund | Yes 43 (21.18) No 160 (78.82) |
| Software used | SPSS 95 (46.80) Stata 9 (4.43) Others 99 (48.77) |
pharmacoeconomics researchers to notice normative standards in health economic studies.

Regarding the limitations of this study, there may be selection bias for included papers. Language and regional barriers are restrictions for authors to search for more papers that meet the inclusion criteria. It could be difficult for many researchers at home to read publications in foreign journals, especially those published in a foreign language [24, 25]. For example, if a Japanese scholar wants to look for some information about Chinese medicine, they might find it difficult to obtain access to certain Chinese databases that include studies about Chinese medicine because the scholar’s institute has not paid for the databases or for other reasons. In this research, we focused on literature in English and Chinese, while papers written in other languages were not considered, which might cause selection bias.

During the appraisal period, some disadvantages of the QHES and CHEERS checklists appeared to be unscientific to some extent [26] because many studies provided more information about methodology, explanations about bias, and so on in detail. Besides, the subjective score would bring injustice to the scoring results. A new checklist of an evaluation tool that is specific for pharmacoeconomic studies is needed and it may solve these problems in later practice [27].

### Table 3: QHES scoring result of methodological quality evaluation.

| Item | Score | Reference range |
|------|-------|-----------------|
| Item 1 | 3.91 ± 2.26 | 0–7 |
| Item 2 | 1.66 ± 0.21 | 0–4 |
| Item 3 | 5.46 ± 0.93 | 0–8 |
| Item 5 | 4.69 ± 2.17 | 0–9 |
| Item 6 | 3.31 ± 2.62 | 0–6 |
| Item 7 | 1.64 ± 0.73 | 0–5 |
| Item 8 | 5.48 ± 1.65 | 0–7 |
| Item 9 | 5.54 ± 0.54 | 0–8 |
| Item 10 | 4.34 ± 1.95 | 0–6 |
| Item 11 | 4.07 ± 1.19 | 0–7 |
| Item 12 | 0.78 ± 2.16 | 0–8 |
| Item 13 | 0.21 ± 0.38 | 0–7 |
| Item 14 | 0.64 ± 1.43 | 0–6 |
| Item 15 | 3.73 ± 1.05 | 0–8 |
| Item 16 | 0.16 ± 0.32 | 0–3 |
| Total (except Item 4) | 45.31 ± 11.47 | 0–99 |

### Table 4: Reporting quality results based on the CHEERS checklist.

| Item | Fully reported | Partially reported | Unreported |
|------|----------------|--------------------|------------|
| Item 1 | 200 (98.52) | (0.946, 0.992) | 3 (1.48) | (0.007, 0.021) |
| Item 2 | 17 (8.37) | (0.072, 0.093) | 179 (88.18) | (0.864, 0.909) | 7 (3.45) | (0.031, 0.037) |
| Item 3 | 197 (97.04) | (0.962, 0.983) | 6 (2.96) | (0.013, 0.0416) | 0 (0.00) | (0, 0.032) |
| Item 4 | 134 (66.00) | (0.613, 0.714) | 69 (33.99) | (0.245, 0.465) | 0 (0.00) | (0, 0.032) |
| Item 5 | 202 (99.51) | (0.947, 0.999) | 0 (0.00) | (0, 0.032) | 1 (0.49) | (0.001, 0.048) |
| Item 6 | 24 (11.82) | (0.103, 0.154) | 162 (79.80) | (0.612, 0.863) | 27 (13.30) | (0.750, 0.231) |
| Item 7 | 43 (21.18) | (0.190, 0.312) | 160 (78.82) | (0.645, 0.797) | 0 (0.00) | (0, 0.032) |
| Item 8 | 3 (1.48) | (0.007, 0.021) | 200 (98.52) | (0.946, 0.992) | 0 (0.00) | (0, 0.032) |
| Item 9 | 9 (4.43) | (0.334, 0.475) | 3 (1.48) | (0.007, 0.021) | 191 (94.09) | (0.915, 0.968) |
| Item 10 | 195 (96.06) | (0.951, 0.973) | 0 (0.00) | (0, 0.032) | 8 (3.94) | (0.132, 0.429) |
| Item 11 | 42 (20.69) | (0.193, 0.211) | 160 (78.82) | (0.758, 0.810) | 1 (0.49) | (0.001, 0.048) |
| Item 12 | 174 (85.71) | (0.856, 0.861) | 20 (9.85) | (0.083, 0.122) | 9 (4.33) | (0.043, 0.476) |
| Item 13 | 65 (32.02) | (0.946, 0.992) | 133 (65.52) | (0.589, 0.682) | 5 (2.46) | (0.023, 0.027) |
| Item 14 | 11 (5.42) | (0.050, 0.076) | 9 (4.43) | (0.038, 0.047) | 183 (90.15) | (0.876, 0.946) |
| Item 15 | 11 (5.42) | (0.050, 0.076) | 10 (4.93) | (0.043, 0.058) | 182 (98.66) | (0.879, 0.921) |
| Item 16 | 131 (64.53) | (0.608, 0.661) | 36 (17.73) | (0.160, 0.183) | 36 (17.73) | (0.134, 0.193) |
| Item 17 | 8 (3.94) | (0.016, 0.044) | 195 (96.06) | (0.943, 0.988) | 0 (0.00) | (0, 0.032) |
| Item 18 | 102 (50.25) | (0.475, 0.539) | 44 (21.47) | (0.201, 0.232) | 57 (28.02) | (0.226, 0.329) |
| Item 19 | 21 (10.34) | (0.094, 0.116) | 94 (46.31) | (0.392, 0.514) | 88 (43.35) | (0.346, 0.471) |
| Item 20 | 146 (71.32) | (0.702, 0.731) | 0 (0.00) | (0, 0.032) | 57 (28.68) | (0.235, 0.313) |
| Item 21 | 19 (9.36) | (0.082, 0.117) | 184 (90.64) | (0.876, 0.931) | 0 (0.00) | (0, 0.032) |
| Item 22 | 24 (11.82) | (0.099, 0.136) | 0 (0.00) | (0, 0.032) | 179 (88.18) | (0.841, 0.932) |
| Item 23 | 2 (0.98) | (0.004, 0.015) | 4 (1.97) | (0.011, 0.029) | 197 (97.05) | (0.962, 0.983) |

Total X ± SD (range) 13.44 ± 0.73 (9–16.5)
5. Conclusions

Against the background of few antivirals found by humans, the significance of antiviral drugs, including TCM and non-TCM, was highlighted. A quality appraisal in pharmacoeconomics was urgently needed to reveal the shortcomings of certain modern evaluations in the field of fighting against virus infection. TCM is proved to be safe, effective, and economic when used to treat virus infection, and this led to the original purpose of our research. In our research, the overall level of literature’s quality about antiviral TCM is still low at 41.37 ± 4.46 in the QHES scoring compared to 48.89 ± 7.25 of antiviral non-TCM. This may be due to the executors of pharmacoeconomic studies, most of whom were pharmacists. Thus, space remains for improving their educational background and clarifying their inspiration for conducting economic research to make their studies more purposeful and of higher quality. One more thing that warrants attention is that a new evaluation tool that is better suited to pharmacoeconomics needs to be invented to meet modern scientific research demands.

Data Availability

The data supporting the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] J. H. Chen, C. J. Perry, Y.-C. Tsui et al., “Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection,” *Nature Medicine*, vol. 21, no. 4, pp. 327–334, 2015.
[2] K. W. Martin and E. Ernst, “Antiviral agents from plants and herbs: a systematic review,” *Antiviral Therapy*, vol. 8, no. 2, pp. 77–90, 2003.
[3] M. Akram, I. M. Tahir, S. M. A. Shah et al., “Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review,” *Phytotherapy Research*, vol. 32, no. 5, pp. 811–822, 2018.
[4] Y. Furuse and H. Oshitani, “Viruses that can and cannot coexist with humans and the future of SARS-CoV-2,” *Frontiers in Microbiology*, vol. 11, Article ID 583252, 2020.
[5] J.-L. Ren, A.-H. Zhang, and X.-J. Wang, “Traditional Chinese medicine for COVID-19 treatment,” *Pharmacological Research*, vol. 155, Article ID 104743, 2020.
[6] Y. L. Zhang, Q. Cui, D. Zhang, X. Ma, and G. W. Zhang, “Efficacy of Xuebijing injection for the treatment of coronavirus disease 2019 via network pharmacology,” *Traditional Medicine Research*, vol. 5, no. 4, pp. 201–215, 2020.
[7] L. Runfeng, H. Yunlong, H. Icheng et al., “Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2),” *Pharmacological Research*, vol. 156, Article ID 104761, 2020.
[8] H. T. Cui, Y. T. Li, L. Y. Guo et al., “Traditional Chinese medicine for treatment of coronavirus disease 2019: a review,” *Traditional Medicine Research*, vol. 5, no. 2, pp. 65–73, 2020.
[9] Z. W. Dujun, “The research development of pharmacoeconomic evaluation on traditional Chinese medicine,” *China Journal of Pharmaceutical Economics*, vol. 5, 2009.
[10] R. D. Durai, “Drug delivery approaches of an antiviral drug: a comprehensive review,” *Asian Journal of Pharmacaceutics (AJP)*, vol. 9, no. 1, pp. 1–12, 2015.
[11] W.-J. Xu, L.-T. Wang, Z.-P. Zhao et al., “Prospects of a comprehensive evaluation system for traditional Chinese medicine services,” *Journal of Integrative Medicine*, vol. 15, no. 6, pp. 426–432, 2017.
[12] Y. Du, L. I. Can, G. Fang, M.-J. Wang, X. Jiang, and P.-C. Liu, “Research and enlightenment of quality assessment scale for medical insurance drugs’ economic evaluation,” *Health Economics Research*, vol. 398, pp. 30–34, 2020.
[13] J. J. Ofman, S. D. Sullivan, P. J. Neumann et al., “Examining the value and quality of health economic analyses: implications of utilizing the QHES,” *Journal of Managed Care Pharmacy*, vol. 9, no. 1, pp. 53–61, 2003.
[14] M.-H. Li, L. I. Hong-Chao, and M. A. Ai-Xia, “Pharmacoeconomic evaluation studies in China: status quo, problems and suggestions,” *China Pharmacy*, vol. 11, 2008.

**Table 5: Comparison of QHES scores of Chinese medicine and non-Chinese medicine.**

| Item   | Antiviral TCM | Antiviral non-TCM | MD      | P value |
|--------|---------------|-------------------|---------|---------|
| Item 1 | 4.02 ± 3.48   | 3.85 ± 2.12       | 0.32 (0.12, 0.51) | 0.43     |
| Item 2 | 1.52 ± 0.31   | 2.14 ± 0.35       | −0.65 (−0.86, −0.43) | 0.12     |
| Item 3 | 4.49 ± 0.70   | 5.52 ± 0.56       | −1.04 (−1.36, −0.68) | 0.65     |
| Item 4 | 4.23 ± 3.13   | 5.21 ± 0.84       | −1.17 (−1.76, −0.63) | 0.44     |
| Item 5 | 3.18 ± 4.91   | 3.54 ± 1.56       | −0.46 (−0.63, −0.42) | 0.62     |
| Item 6 | 0.79 ± 1.22   | 1.93 ± 0.71       | −1.16 (−1.32, −1.08) | 0.01*    |
| Item 7 | 5.25 ± 1.37   | 5.85 ± 2.11       | −0.61 (−0.84, −0.47) | 0.56     |
| Item 8 | 5.61 ± 0.63   | 5.52 ± 0.45       | 0.15 (0.12, 0.17) | 0.83     |
| Item 9 | 4.25 ± 1.99   | 4.51 ± 1.27       | −0.39 (−0.42, −0.33) | 0.59     |
| Item 10| 3.73 ± 0.54   | 4.18 ± 1.89       | −0.47 (−0.81, −0.10) | 0.43     |
| Item 11| 0.06 ± 5.13   | 1.18 ± 4.64       | −1.02 (−1.64, −0.56) | ≤0.01*   |
| Item 12| 0.43 ± 0.36   | 0.77 ± 4.41       | −0.59 (−0.67, −0.54) | 0.03*    |
| Item 13| 1.22 ± 1.93   | 1.22 ± 1.93       | 0.00 (−0.37, −0.29) | 0.98     |
| Item 14| 3.48 ± 3.85   | 3.48 ± 3.85       | 0.00 (−0.71, −0.70) | 0.03*    |

*P < 0.05.
[15] X. Wang, Z.-F. Wang, Z.-F. Wang et al., "Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation," *Chinese Journal of Integrative Medicine*, vol. 21, no. 6, pp. 473–480, 2015.

[16] B. R. Motheral, "Assessing the value of the quality of health economic studies (QHES)," *Journal of Managed Care Pharmacy*, vol. 9, no. 1, pp. 86-87, 2003.

[17] S. Sanghera, E. Frew, and T. Roberts, "Adapting the CHEERS statement for reporting cost-benefit analysis," *Pharmacoconomics*, vol. 33, 2015.

[18] J. Gallagher, S. McCarthy, and S. Byrne, "Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature," *International Journal of Clinical Pharmacy*, vol. 36, no. 6, pp. 1101–1114, 2014.

[19] L. M. Jolicoeur, A. J. Jones-Grizzle, and J. G. Boyer, "Guidelines for performing a pharmacoeconomic analysis," *American Journal of Health-System Pharmacy*, vol. 49, no. 7, pp. 1741–1747, 1992.

[20] F. Zhang, X. He, W. Xiang, and S. C. Li, "Assessment of the quality of pharmacoeconomic evaluation literature in China," *Journal of Medical Economics*, vol. 20, no. 5, pp. 510–517, 2017.

[21] T.-L. Shi, J. Ling, S. Ai-Zong, S. Yan-Cai, and S.-Y. Zhang, "Study on the development of clinical pharmacist work in China by bibliometrics," *China Pharmacy*, vol. 25, 2010.

[22] S. Farid, M. Elmahdawy, and D. Baines, "A systematic review on the extent and quality of pharmacoeconomic publications in Egypt," *Clinical Drug Investigation*, vol. 39, no. 2, pp. 157–168, 2019.

[23] M. Acharya, "Pharmacoeconomic studies in Nepal: the need of the hour," *Frontiers in Pharmacology*, vol. 5, p. 272, 2014.

[24] A. Squires, "Methodological challenges in cross-language qualitative research: a research review," *International Journal of Nursing Studies*, vol. 46, no. 2, pp. 277–287, 2009.

[25] S. Gottschalk, V. Bernacchi, R. Rogers, and E. Demidova, "Towards better understanding researcher strategies in cross-lingual event analytics," in *Digital Libraries for Open Knowledge*. Springer, Cham, Switzerland, 2018.

[26] D. Husereau, M. Drummond, S. Petrou et al., "Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force," *Value in Health*, vol. 16, no. 2, pp. 231–250, 2013.

[27] M. Barbieri, M. Drummond, F. Rutten et al., "What do international pharmacoeconomic guidelines say about economic data transferability?" *Value in Health*, vol. 13, no. 8, pp. 1028–1037, 2010.